Recon: Sanofi to build new €1.3B insulin plant in Frankfurt; Novo launches Wegovy in Australia

• Lilly says weight loss drug cuts heart failure risk by 38% in trial (Reuters)
• Lilly CEO says weight-loss drug shortage to end 'very soon', Bloomberg News reports (Reuters)
• Biogen lifts profit forecast, signals progress in turnaround effort (Reuters)
• Moderna cuts 2024 sales forecast, sees low EU vaccine revenue into 2026 (Reuters)
• The health care records of 5 leading candidates to be Harris’ VP (STAT)
• With Biden’s departure in sight, advocates seek to preserve gains of Cancer Moonshot (STAT)
• 23andMe CEO proposes to take company private (MedtechDive)
• It took more than two decades for MDMA to reach the FDA. In two months, its prospects cracked. What happens next? (Endpoints)

• Sanofi to invest 1.3 bln euros in new insulin plant in Frankfurt (Reuters)
• Novo Nordisk launches weight-loss drug Wegovy in Australia (Reuters)
• Indian drugmaker Sun Pharma posts Q1 profit beat on strong local sales (Reuters)
• Behind the malaria vaccines: A 40-year quest against one of humanity’s biggest killers (STAT)
• Otsuka buys startup Jnana, adding to uptick in private biotech M&A (BioPharmaDive)

• Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest (Reuters)
• Merck raises outlook for electronics and healthcare, sees improved chip market demand (Reuters)
• Pfizer mulls facility sale; GSK penalized in South Korea for administrative breach (Endpoints)
• Jim Wilson, gene therapy pioneer, departs Penn to set up new companies (STAT)
• Takeda's Entyvio holds onto IBD market share despite threat from AbbVie's Skyrizi (Fierce)
• Teva factored IRA's next round of negotiations into its growth plans (Endpoints)
• FibroGen to shrink US workforce by 75% following more late-stage fails (Endpoints)
• FDA questions Zevra’s resubmitted data for rare disease drug ahead of adcomm (Endpoints)
• FDA shoots down second Novartis petition seeking to halt Entresto generics (Endpoints)
• Bayer lops off 70 more employees at New Jersey headquarters (Fierce)
• Valneva pays LimmaTech $10M for clinical-stage Shigella vaccine (Fierce)
• Sage changes main endpoint in Huntington's study months ahead of readout (Endpoints)
• After norovirus vaccine's trial failure, HilleVax lays off 40% of staff (Endpoints)
• EMA To Revamp Pre-Submission Dialog For Smoother Drug Reviews (Pink Sheet)
• EMA Tackles Rising Cardiovascular Risks Of Cancer Treatments (Pink Sheet)

• Europe’s Medtech Market Is Going Strong, Medtech Europe Reports (MedtechInsight)
• Becton Dickinson tops profit estimates on demand for drug-delivery devices (Reuters)
• Teleflex raises 2024 profit forecast on medical device demand (Reuters)
• Smith & Nephew jumps to one-year high as profit beats estimates (Reuters)
• Labcorp beats Q2 profit and revenue estimates on demand for health tests (Reuters)
• Labcorp expands Ultima pact to boost genomic diagnostics (MedtechDive)
• FDA sends warning letter to defibrillator battery manufacturer (MedtechDive)
• FDA, Health Canada team up to raise awareness of J&J’s Megadyne recall (MedtechDive)
• CMR Surgical Kick Off Pediatric Clinical Trial With Surgical Robot Versius (MedtechInsight)
• Stryker plans ‘very active’ M&A, ortho robot launches in 2H (MedtechDive)

• Rising rates of skin cancer: The cost of FDA’s inaction on novel sunscreen products (STAT)
• Del. Judge Clears Lupin's Generic Kidney Disease Drug (Law360)
• Judge rejects Novo Nordisk's IRA case as pricing negotiations conclude (Endpoints)
• Could SCOTUS Chevron Reversal Reverse FDA’s Final Rule On LDTs? (MedtechInsight)